WeVote
Log In

Bill

Bill

SF 1340

Utilization review for prescription drug coverage modification

2025-2026 Regular Session Introduced by Susan Pha

Minnesota bill requiring insurers to provide advance notice, clinical justification, and appeal rights when restricting or eliminating prescription drug coverage.

Referred to Commerce and Consumer Protection
#drugsandmedicine #healthandhealthdepartment #insurance-health
0
WeVote Research Nonpartisan
Bill Summary · SF 1340

Legislative bill overview

SF 1340 establishes requirements for utilization review processes when health insurers propose to modify, restrict, or discontinue coverage of prescription drugs. The bill mandates that insurers provide healthcare providers and patients with advance notice, clinical justification, and appeal opportunities before implementing such coverage changes.

Why is this important

Prescription drug coverage modifications can significantly affect patient access to medications and treatment continuity. Clear utilization review standards protect patients from unexpected coverage losses while giving insurers defined procedures for managing drug formularies, potentially reducing disputes between insurers, providers, and patients.

Potential points of contention

  • Insurance industry concerns: Insurers may argue that standardized review requirements increase administrative costs and limit their ability to manage drug costs and formulary decisions flexibly
  • Implementation timeline and burden: Defining what constitutes adequate "advance notice" and "clinical justification" could create disputes and operational challenges for health plans
  • Scope of coverage changes: Unclear whether the bill applies to all formulary modifications or only major restrictions, potentially affecting how broadly it impacts insurance practices

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.